Evidence map›Paper›PMID 38352054›Full record

ArticleFrontiers in cellular and infection microbiology2024

Nanopore sequencing of infectious fluid is a promising supplement for gold-standard culture in real-world clinical scenario.

Manna Zhao, Yongyang Zhang, Li Chen, Xuebing Yan, Tianmin Xu, Maoying Fu, Yangguang Han, Ying Zhang, Bin Zhang, Juan Cao and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 1 country.

Manna Zhao *Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Yongyang Zhang *Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
Li Chen *Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Xuebing YanDepartment of Infectious Disease, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Tianmin XuDepartment of Infectious Diseases, The Third People's Hospital of Changzhou, Changzhou, Jiangsu, China.
Maoying FuInfectious Diseases Department, Kunshan First People's Hospital, Kunshan, Jiangsu, China.
Yangguang HanDepartment of Infectious Diseases, The Affiliated People's Hospital of Jiangsu University, Zhenjiang, Jiangsu, China.
Ying ZhangDepartment of Infection Medicine, The Fifth People's Hospital of Wuxi, Affiliated Wuxi Fifth Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Bin ZhangDepartment of Infectious Diseases, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
Juan CaoEmergency Department, Shanghai Shibei Hospital, Shanghai, China.
Jing LinDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Dan ShenKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd., Hangzhou, Zhejiang, China.
Shuo LiKey Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Dian Diagnostics Group Co., Ltd., Hangzhou, Zhejiang, China.
Chuanlong ZhuDepartment of Infectious Diseases, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Weifeng ZhaoDepartment of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
Dian Diagnostics (China) · CNFirst Affiliated Hospital of Soochow University · CNNanjing Drum Tower Hospital · CNSoochow University · CNChangzhou Third People's Hospital · CNFirst People's Hospital of Kunshan · CNJiangsu Province Hospital · CNJiangsu University · CNNantong University · CNShanghai Zhabei District Shibei Hospital · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Infectious diseases are major causes of morbidity and mortality worldwide, necessitating the rapid identification and accurate diagnosis of pathogens. While unbiased metagenomic next-generation sequencing (mNGS) has been extensively utilized in clinical pathogen identification and scientific microbiome detection, there is limited research about the application of nanopore platform-based mNGS in the diagnostic performance of various infectious fluid samples. Methods: In this study, we collected 297 suspected infectious fluids from 10 clinical centers and detected them with conventional microbiology culture and nanopore platform-based mNGS. The objective was to assess detective and diagnostic performance of nanopore-sequencing technology (NST) in real-world scenarios. Results: Combined with gold-standard culture and clinical adjudication, nanopore sequencing demonstrated nearly 100% positive predictive agreements in microbial-colonized sites, such as the respiratory and urinary tracts. For samples collected from initially sterile body sites, the detected microorganisms were highly suspected pathogens, and the negative predictive agreements were relatively higher than those in the microbial-colonized sites, particularly with 100% in abscess and 95.7% in cerebrospinal fluid. Furthermore, consistent performance was also observed in the identification of antimicrobial resistance genes and drug susceptibility testing of pathogenic strains of Discussion: Rapid NST is a promising clinical tool to supplement gold-standard culture, and it has the potential improve patient prognosis and facilitate clinical treatment of infectious diseases.

Indexed as

Communicable DiseasesMycobacterium tuberculosisNanopore SequencingStaphylococcal InfectionsEscherichia coliHigh-Throughput Nucleotide SequencingHumansMetagenomicsMicrobial Sensitivity TestsSensitivity and Specificitydiagnosisinfectious body fluidsinfectious diseasesmetagenomic next-generation sequencing (mNGS)nanopore sequencing technology (NST)

Identifiers

PMID38352054
PMCPMC10861792
OpenAlexW4391358736

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.